VIA
MREO

Virtus Investment Advisers’s Mereo BioPharma MREO Stock Holding History

Virtus Investment Advisers’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.5K Buy
125,662
+3,067
+3% +$1.32K 0.01% 449
2025
Q4 		$51.1K Buy
122,595
+81,665
+200% +$155K 0.01% 461
2025
Q3 		$84.3K Buy
40,930
+7,105
+21% +$13.1K 0.02% 432
2025
Q2 		$91.7K Sell
33,825
-10,182
-23% -$24.6K 0.03% 370
2025
Q1 		$99K Buy
+44,007
New +$124K 0.03% 423

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Virtus Investment Advisers's MREO Position: Q1 2026 in Review

Virtus Investment Advisers increased its Mereo BioPharma (MREO) stake by 2.5% in Q1 2026, buying an estimated $1.32K and bringing the position to 125,662 shares worth $41.5K. The position accounts for 0.01% of the portfolio, ranked #449.

Virtus Investment Advisers first reported a position in MREO in Q1 2025 and has held it in 5 quarters since. The position peaked at $99K in Q1 2025. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Virtus Investment Advisers held 125,662 shares of Mereo BioPharma worth $41.5K as of Q1 2026.
  • Virtus Investment Advisers bought 3,067 Mereo BioPharma shares in Q1 2026, an estimated $1.32K.
  • Mereo BioPharma made up 0.01% of Virtus Investment Advisers's portfolio in Q1 2026, its #449 holding.
  • Virtus Investment Advisers first reported a position in Mereo BioPharma in Q1 2025 and has held it in 5 quarters since.
  • Virtus Investment Advisers's Mereo BioPharma position peaked at $99K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.